129 related articles for article (PubMed ID: 33323405)
1. Unbiased Detection of Driver Mutations in Extramammary Paget Disease.
Ishida Y; Kakiuchi N; Yoshida K; Inoue Y; Irie H; Kataoka TR; Hirata M; Funakoshi T; Matsushita S; Hata H; Uchi H; Yamamoto Y; Fujisawa Y; Fujimura T; Saiki R; Takeuchi K; Shiraishi Y; Chiba K; Tanaka H; Otsuka A; Miyano S; Kabashima K; Ogawa S
Clin Cancer Res; 2021 Mar; 27(6):1756-1765. PubMed ID: 33323405
[TBL] [Abstract][Full Text] [Related]
2. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
[TBL] [Abstract][Full Text] [Related]
5. Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.
Zhang G; Zhou S; Zhong W; Hong L; Wang Y; Lu S; Pan J; Huang Y; Su M; Crawford R; Zhou Y; Mai R
J Invest Dermatol; 2019 Apr; 139(4):789-795. PubMed ID: 30905357
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.
Hirai I; Tanese K; Nakamura Y; Otsuka A; Fujisawa Y; Yamamoto Y; Hata H; Fujimura T; Matsushita S; Yoshino K; Kameyama K; Amagai M; Funakoshi T
Med Oncol; 2018 May; 35(6):92. PubMed ID: 29744813
[TBL] [Abstract][Full Text] [Related]
7. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Takahashi A; Tsutsumida A; Fujisawa Y; Fujimoto M; Yamazaki N
Clin Exp Metastasis; 2016 Oct; 33(7):687-97. PubMed ID: 27289366
[TBL] [Abstract][Full Text] [Related]
8. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease.
Miyamoto A; Akasaka K; Oikawa H; Akasaka T; Masuda T; Maesawa C
Am J Dermatopathol; 2010 Aug; 32(6):578-85. PubMed ID: 20534991
[TBL] [Abstract][Full Text] [Related]
10. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
12. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.
Adam L; San Lucas FA; Fowler R; Yu Y; Wu W; Liu Y; Wang H; Menter D; Tetzlaff MT; Ensor J; Manyam G; Arold ST; Huff C; Kopetz S; Scheet P; Overman MJ
Clin Cancer Res; 2019 Jan; 25(2):641-651. PubMed ID: 30352910
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
14. Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget's disease.
Kusaba Y; Kajihara I; Myangat TM; Tanaka K; Sakamoto R; Maeda-Otsuka S; Yamada-Kanazawa S; Sawamura S; Kanemaru H; Nishimura Y; Nakamura-Kashiwada K; Makino K; Miyashita A; Aoi J; Masuguchi S; Fukushima S
J Dermatol; 2022 May; 49(5):508-514. PubMed ID: 35253277
[TBL] [Abstract][Full Text] [Related]
15. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing identified mutational profiles of squamous cell carcinomas of anus.
Shin S; Park HC; Kim MS; Han MR; Lee SH; Jung SH; Lee SH; Chung YJ
Hum Pathol; 2018 Oct; 80():1-10. PubMed ID: 29555573
[TBL] [Abstract][Full Text] [Related]
18. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease.
Perrotto J; Abbott JJ; Ceilley RI; Ahmed I
Am J Dermatopathol; 2010 Apr; 32(2):137-43. PubMed ID: 20051815
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
